Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript

Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 14, 2026

Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil

ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.

Zacks Investment Research • May 14, 2026

Altimmune Q1 Earnings Call Highlights

Altimmune NASDAQ: ALT said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, in the second half of 2026, as the company reported first-quarter financial results and provided updates across its liver disease pipeline.

MarketBeat • May 13, 2026

Altimmune Announces First Quarter 2026 Financial Results and Business Update

Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.

GlobeNewsWire • May 13, 2026

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL

GlobeNewsWire • May 13, 2026

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026.

GlobeNewsWire • May 6, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with participation from TCGX, Viking Global Investors, RA Capital Management, and other new and existing investors GAITHERSBURG, Md., April 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the closing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and 64,250,000 accompanying common stock warrants to purchase shares of common stock or pre-funded warrants in lieu thereof and (ii) in lieu of common stock, to certain investors that so choose, pre-funded warrants to purchase an aggregate of up to 10,750,000 shares of its common stock and 10,750,000 accompanying common stock warrants to purchase shares of common stock or pre-funded warrants in lieu thereof, each at an exercise price of $0.001 per pre-funded warrant.

GlobeNewsWire • Apr 27, 2026

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.

Zacks Investment Research • Apr 23, 2026

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.

Zacks Investment Research • Apr 23, 2026

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.

Zacks Investment Research • Apr 23, 2026